Literature DB >> 18160187

Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.

Josie Haydée L Ferreira1, Luciana Girotto Gentil, Suzana Souza Dias, Carlos Eduardo C Fedeli, Simone Katz, Clara Lúcia Barbiéri.   

Abstract

The gene Ldccys1 encoding a cysteine proteinase of 30 kDa from Leishmania (Leishmania) chagasi, as well as the recombinant cysteine proteinase rLdccys1, obtained by cloning and expression of the Ldccys1 gene in the pHIS vector, were used to evaluate their ability to induce immune protective responses in BALB/c mice against L. (L.) chagasi infection. Mice were immunized subcutaneously with rLdccys1 plus Bacille Calmette Guerin (BCG) or Propionibacterium acnes as adjuvants or intramuscularly with a plasmid carrying the Ldccys1 gene (Ldccys1/pcDNA3) and CpG ODN as the adjuvant, followed by a booster with rLdccys1 plus CpG ODN. Two weeks after immunization the animals were challenged with 1 x 10(7) amastigotes of L. (L.) chagasi. Both immunization protocols induced significant protection against L. (L.) chagasi infection as shown by a very low parasite load in the spleen of immunized mice compared to the non-immunized controls. However, DNA immunization was 10-fold more protective than immunization with the recombinant protein. Whereas rLdccys1 induced a significant secretion of IFN-gamma and nitric oxide (NO), animals immunized with the Ldccys1 gene increased the production of IgG2a antibodies, IFN-gamma and NO. These results indicated that protection triggered by the two immunization protocols was correlated to a predominant Th1 response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160187     DOI: 10.1016/j.vaccine.2007.11.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Leishmania (Viannia) shawi purified antigens confer protection against murine cutaneous leishmaniasis.

Authors:  Luiz Felipe Domingues Passero; Ana Kely Carvalho; Maria Luiza A C Bordon; Alexis Bonfim-Melo; Marcos Hikari Toyama; Carlos Eduardo Pereira Corbett; Márcia Dalastra Laurenti
Journal:  Inflamm Res       Date:  2011-12-14       Impact factor: 4.575

2.  A new immunochemotherapy schedule for visceral leishmaniasis in a hamster model.

Authors:  Fabiana Rodrigues de Santana; Danielle Aparecida Marino da Silva; Simone Katz; Cristina Mary Orikaza; Katia Cristina Oliveira; Clara Lúcia Barbiéri
Journal:  Parasitol Res       Date:  2022-08-23       Impact factor: 2.383

3.  In situ immunolocalization and stage-dependent expression of a secretory serine protease in Leishmania donovani and its role as a vaccine candidate.

Authors:  Rajdeep Choudhury; Partha Das; Siddhartha Kumar Bhaumik; Tripti De; Tapati Chakraborti
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

4.  Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.

Authors:  Mehdi Shahbazi; Farnaz Zahedifard; Tahereh Taheri; Yasaman Taslimi; Shahram Jamshidi; Sadegh Shirian; Niousha Mahdavi; Mehdi Hassankhani; Yahya Daneshbod; Sayyed Hamid Zarkesh-Esfahani; Barbara Papadopoulou; Sima Rafati
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

5.  Treatment of Leishmania (Leishmania) Amazonensis-Infected Mice with a Combination of a Palladacycle Complex and Heat-Killed Propionibacterium acnes Triggers Protective Cellular Immune Responses.

Authors:  Carolina S Paladi; Danielle A M da Silva; Priscila D Motta; Daniel M Garcia; Daniela Teixeira; Ieda M Longo-Maugéri; Simone Katz; Clara L Barbiéri
Journal:  Front Microbiol       Date:  2017-03-06       Impact factor: 5.640

6.  Experimental infection of dogs with Leishmania and saliva as a model to study Canine Visceral Leishmaniasis.

Authors:  Dirceu Joaquim Costa; Rayssa M de Araujo Carvalho; Melissa Abbehusen; Clarissa Teixeira; Maiana Pitombo; Joelma Trigo; Flávia Nascimento; Lucilene Amorim; Ana Lucia Abreu-Silva; Maria do Socorro Pires Cruz; José Carlos Miranda; Kyoshi Fukutani; Camila I de Oliveira; Aldina Barral; Manoel Barral-Netto; Cláudia Brodskyn
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

7.  A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.

Authors:  Connor Carson; Maria Antoniou; Maria Begoña Ruiz-Argüello; Antonio Alcami; Vasiliki Christodoulou; Ippokratis Messaritakis; Jenefer M Blackwell; Orin Courtenay
Journal:  Vaccine       Date:  2008-12-16       Impact factor: 3.641

8.  Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis.

Authors:  Josie Haydée Lima Ferreira; Lucilene Dos Santos Silva; Ieda Maria Longo-Maugéri; Simone Katz; Clara Lúcia Barbiéri
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13

9.  Protective Cellular Immune Response Induction for Cutaneous Leishmaniasis by a New Immunochemotherapy Schedule.

Authors:  Danielle A M da Silva; Fabiana R Santana; Simone Katz; Daniel M Garcia; Daniela Teixeira; Ieda M Longo-Maugéri; Clara L Barbiéri
Journal:  Front Immunol       Date:  2020-03-03       Impact factor: 7.561

10.  Vaccination in Leishmaniasis: A Review Article.

Authors:  Latifeh Abdellahi; Fariba Iraji; Anahita Mahmoudabadi; Seyed Hossein Hejazi
Journal:  Iran Biomed J       Date:  2022-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.